Post Traumatic Stress DisorderNCT07720674
SEE FAR CBT Intervention for Adults With PTSD
A study testing SEE FAR CBT in people with Post Traumatic Stress Disorder, run by Community Stress Prevention Center at 1 site in Israel.
Trial summary
This single-arm clinical intervention study evaluates a 12-session SEE FAR CBT intervention for adults aged 18 years and older with posttraumatic stress disorder (PTSD). SEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Post Traumatic Stress Disorder
- What is being tested?
- SEE FAR CBT
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteIsrael
- Study dates
- Jul 2026to Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must meet all of the following criteria:
- Age 18 years or older
- PTSD symptoms, defined as a PCL-5 score of 30 or above
- Able to provide informed consent
- Willing and able to participate in 12 weekly individual therapy sessions and complete study questionnaires at baseline, post-intervention, and 3-month follow-up Exclusion Criteria
- Participants will be excluded if they meet any of the following criteria:
Show all 9Show fewer
- Pregnancy at the time of enrollment, due to the potential influence of pregnancy and childbirth during the treatment or follow-up period on psychological outcomes.
- Currently receiving psychotherapy of any type that began less than 3 months prior to enrolment.
- Initiation of psychiatric medication less than 3 months prior to enrolment.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Israel1 site, 1 recruiting
- Recruiting
Community Stress Prevention Center
Kiryat Shmona
Meital Mashash, PhD, 972-50-2888052, meitalm@icspc.org
About this study
Official title: A Clinical Study Evaluating the Effects of a SEE FAR CBT Intervention on Psychological Outcomes in Adults With Posttraumatic Stress Disorder.
This single-arm clinical intervention study evaluates a 12-session SEE FAR CBT intervention for adults aged 18 years and older with posttraumatic stress disorder (PTSD). SEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will complete self-report psychological questionnaires at three time points: baseline, after completion of the intervention, and at a 3-month follow-up. The study aims to examine changes in PTSD symptoms and related psychological outcomes over the course of treatment and follow-up.
- Conditions
- Post Traumatic Stress Disorder
- Being tested
- SEE FAR CBT
- Keywords
- PTSD, SEE FAR CBT, Intervention
- Medical subject headings
- Stress Disorders, Post-Traumatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SEE FAR CBTBehavioural
SEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will receive 12 therapeutic sessions delivered approximately once weekly as a structured psychological intervention for PTSD.
| Study group | Role | What they receive |
|---|---|---|
| SEE FAR CBT Intervention | Experimental | Participants in this single-arm study will receive 12 therapeutic sessions of SEE FAR CBT for PTSD, delivered approximately once weekly. Receives: Behavioral: SEE FAR CBT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in PTSD symptoms
PTSD Checklist for DSM-5 (PCL-5). PTSD symptoms will be assessed using the PCL-5. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Change in PCL-5 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Measured: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in anxiety symptoms
Generalized Anxiety Disorder-7 (GAD-7). Anxiety symptoms will be assessed using the GAD-7. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change in GAD-7 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Measured: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Secondary outcomes (5)
Change in depressive symptoms
Patient Health Questionnaire-9 (PHQ-9). Depressive symptoms will be assessed using the PHQ-9. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Change in PHQ-9 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Measured: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in perceived stress
Perceived Stress Scale (PSS). Perceived stress will be assessed using the PSS. Total scores range from 0 to 40, with higher scores indicating greater perceived stress. Change in PSS total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Measured: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in resilience
Connor-Davidson Resilience Scale (CD-RISC-10). Resilience will be assessed using the CD-RISC. Total scores range from 0 to 40, with higher scores indicating greater resilience. Change in CD-RISC total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Measured: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in somatic symptoms
Patient Health Questionnaire-15 (PHQ-15). Somatic symptoms will be assessed using the PHQ-15. Total scores range from 0 to 30, with higher scores indicating greater somatic symptom severity. Change in PHQ-15 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Measured: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in trauma-related use of imagination and coping
Fantastic Reality Ability Measurement (FRAME). Trauma-related use of imagination and coping will be assessed using the FRAME questionnaire. The FRAME is a 21-item measure of fantastic reality ability, defined as the capacity to use imagination in response to stress or trauma. Items are rated on a 1-7 Likert scale, and mean scores range from 1 to 7, with higher scores indicating greater fantastic reality ability. Change in FRAME score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Measured: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2026
- Study startJul 2026 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post Traumatic Stress DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All participants will be assigned to a single group and will receive the 12-session SEE FAR CBT intervention. There is no control or comparison group.
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Community Stress Prevention Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Meital Mashash, PhD, Principal investigator, Community Stress Prevention CenterSivan Raz, PhD, Principal investigator, Tel Hai College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07720674
- Sponsor's protocol ID
- SEE-FAR-CBT-PTSD-NORTH-2026
- Status last verified
- Jun 2026
- First submitted
- 1 Jul 2026
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to the sensitive clinical nature of the data and participant privacy considerations.
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study Evaluating the Effects of a SEE FAR CBT Intervention on Psychological Outcomes in Adults With Posttraumatic Stress Disorder.
- ClinicalTrials.gov ID
- NCT07720674
- Acronym / sponsor ID
- SEE-FAR-CBT-PTSD-NORTH-2026
- Conditions
- Post Traumatic Stress Disorder
- Keywords
- PTSD, SEE FAR CBT, Intervention
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Community Stress Prevention CenterUniversity, hospital or other
- Study start
- Jul 2026 (estimated)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 22 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single-arm clinical intervention study evaluates a 12-session SEE FAR CBT intervention for adults aged 18 years and older with posttraumatic stress disorder (PTSD). SEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will complete self-report psychological questionnaires at three time points: baseline, after completion of the intervention, and at a 3-month follow-up. The study aims to examine changes in PTSD symptoms and related psychological outcomes over the course of treatment and follow-up.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All participants will be assigned to a single group and will receive the 12-session SEE FAR CBT intervention. There is no control or comparison group.
| Arm | Type | Receives |
|---|---|---|
| SEE FAR CBT Intervention | Experimental | Behavioral: SEE FAR CBTParticipants in this single-arm study will receive 12 therapeutic sessions of SEE FAR CBT for PTSD, delivered approximately once weekly. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age 18 years or older
- PTSD symptoms, defined as a PCL-5 score of 30 or above
- Able to provide informed consent
- Willing and able to participate in 12 weekly individual therapy sessions and complete study questionnaires at baseline, post-intervention, and 3-month follow-up Exclusion Criteria
- Pregnancy at the time of enrollment, due to the potential influence of pregnancy and childbirth during the treatment or follow-up period on psychological outcomes.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SEE FAR CBTSEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will receive 12 therapeutic sessions delivered approximately once weekly as a structured psychological intervention for PTSD. | Behavioural | SEE FAR CBT Intervention |
Primary outcome
Change in PTSD symptoms
Time frame: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
PTSD Checklist for DSM-5 (PCL-5). PTSD symptoms will be assessed using the PCL-5. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Change in PCL-5 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Change in anxiety symptoms
Time frame: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Generalized Anxiety Disorder-7 (GAD-7). Anxiety symptoms will be assessed using the GAD-7. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change in GAD-7 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
5 secondary outcomes
Change in depressive symptoms
Time frame: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in perceived stress
Time frame: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in resilience
Time frame: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in somatic symptoms
Time frame: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in trauma-related use of imagination and coping
Time frame: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to the sensitive clinical nature of the data and participant privacy considerations.
Related trials for Post Traumatic Stress Disorder
Active, not recruiting
Improving Student Mental Health Through a Universal Trauma-Informed Intervention
Anxiety Symptoms, Post-traumatic Stress Symptoms
RecruitingPhase 1
Open-Label Psilocybin Study in Transdiagnostic Population
Transdiagnostic, Depression - Major Depressive Disorder
Not yet recruitingPhase 2
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PTSD, PTSD - Post Traumatic Stress Disorder
Active, not recruitingObservational study
Trauma-Related Attributions in Trauma Treatment: An Observational Study
PTSD
Not yet recruiting
Multimodal Intervention for Individuals With Posttraumatic Stress Disorder (PTSD) and Hazardous Alcohol Use
Post Traumatic Stress Disorder PTSD, Hazardous Alcohol Use
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Meital Mashash, PhD principal investigator
Community Stress Prevention Center
Sivan Raz, PhD principal investigator
Tel Hai College
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SEE FAR CBT in people with Post Traumatic Stress Disorder, run by Community Stress Prevention Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Meital Mashash, PhD (972-50-2888052, meitalm@icspc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in PTSD symptoms (time frame: Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.